Janssen Global Services, LLC

Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study (2024) Taylor PC, Schett G, Huizinga TW, Wang Q, Ibrahim F, Zhou B, Liva SG, et al. Journal article Can the General Public Be a Proxy for an “At-Risk” Group in a Patient Preference Study? A Disease Prevention Example in Rheumatoid Arthritis (2024) DiSantostefano RL, Simons G, Englbrecht M, Humphreys JH, Bruce IN, Bywall KS, Radawski C, et al. Journal article Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial (2024) Siebert S, Schett G, Raychaudhuri SP, Guma M, Chen W, Gao S, Chakravarty SD, et al. Journal article LONGITUDINAL MODELING OF DEPRESSION SHIFTS USING SPEECH AND LANGUAGE (2024) Perez Toro PA, Dineley J, Kaczkowska A, Conde P, Zhang Y, Matcham F, Siddi S, et al. Conference contribution Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis (2024) Siebert S, Coates LC, Schett G, Raychaudhuri SP, Chen W, Gao S, Seridi L, et al. Journal article Regulatory Issues of Platform Trials: Learnings from EU-PEARL (2024) Nguyen QL, Hees K, Hernandez Penna S, König F, Posch M, Bofill Roig M, Meyer EL, et al. Journal article, Review article Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis (2024) Rahman P, McInnes IB, Deodhar A, Schett G, Mease PJ, Shawi M, Cua DJ, et al. Journal article Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study (2023) Schett G, Chen W, Gao S, Chakravarty SD, Shawi M, Lavie F, Zimmermann M, et al. Journal article Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non-interventional, prospective, German multicentre PERSIST study (2023) Gerdes S, Hoffmann M, Asadullah K, Korge B, Mortazawi D, Krüger N, Personke Y, et al. Journal article Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study. (2023) Schett G, Chen W, Gao S, Chakravarty SD, Shawi M, Lavie F, Zimmermann M, et al. Journal article, Erratum